share_log

The Analyst Verdict: Mersana Therapeutics In The Eyes Of 5 Experts

Benzinga ·  Mar 19 09:00

5 analysts have shared their evaluations of Mersana Therapeutics (NASDAQ:MRSN) during the recent three months, expressing a mix of bullish and bearish perspectives.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings21200
Last 30D00100
1M Ago21100
2M Ago00000
3M Ago00000

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $6.6, a high estimate of $9.00, and a low estimate of $5.00. Witnessing a positive shift, the current average has risen by 65.0% from the previous average price target of $4.00.

price target chart

Analyzing Analyst Ratings: A Detailed Breakdown

The analysis of recent...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment